Vytorin: No Proof It Works, No Proof It Causes Cancer

In 2002, when the US Food and Drug Administraiton (FDA) approved the generic drug, ezetimibe, for its ability to lower cholesterol, the agency did so on the basis of just a few very small clinical trials of very short duration, all of them conducted by the very people who would market the drug. Since then, controversy has surrounded Vytorin and Zetia, two brand-name drugs containing ezetimibe. It seems that there is no conclusive proof that it works and no conclusive proof that it causes cancer. Or not. Read more

Vytorin Continues to Break Hearts at Merck, Schering

The bad news just seems to keep coming.  The results of the latest test of the prescription drug, Vytorin, show the drug produced no significant indication that it is effective in the treatment of aortic valve disease and heart disease.  The test also showed that Vytorin actually increased the number of heart events deemed “serious” when cancer patients take the drug. Read more